Mutational and oxidative stress analysis in patients with mucopolysaccharidosis type I undergoing enzyme replacement therapy

被引:48
|
作者
Pereira, Vanessa Goncalves
Martins, Ana Maria
Micheletti, Cecilia
D'Almeida, Vania
机构
[1] Univ Fed Sao Paulo, Dept Pediat, Inst Genet & Inborn Errors Metab, Sao Paulo, Brazil
[2] Univ Fed Sao Paulo, Dept Hlth Sci, Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
mucopolysaccharidosis type I; alpha-L-iduronidase; IDUA gene; enzyme replacement therapy; oxidative stress;
D O I
10.1016/j.cca.2007.09.008
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Mucopolysaccharidosis type I (NIPS 1) patients present a wide range of clinical manifestations, which could be due to the high molecular heterogeneity of the IDUA gene and to pathological events besides the enzyme deficiency. The aim of this study was to identify the most common MPS I causing mutations and to evaluate some oxidative stress markers in Brazilian patients. Methods: 3 common mutations in the IDUA gene were searched in 11 MPS I patients by PCR-RFLP. Activities of antioxidant enzymes catalase and superoxide dismutase, and levels of total glutathione and thiobarbituric acid reactive substances were evaluated by spectrophotometric and colorimetric methods, during different periods of enzyme replacement therapy. Results: The most common mutations were P533R and W402X, with allelic frequencies of 33.33% and 27.8% respectively. MPS I patients presented high levels of lipid peroxidation and enzyme replacement therapy led to an increase of catalase and a decrease of superoxide dismutase activities. Conclusions: P533R and W402X accounted for more than 60% of the alleles, but no genotype-phenotype correlation could be established. The alterations in antioxidant enzyme activities suggest that oxidative stress may be an important event among MPS I patients, which could contribute to the physiopathology of the disease. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:75 / 79
页数:5
相关论文
共 50 条
  • [1] Mutational analysis of mucopolysaccharidosis type VI patients undergoing a trial of enzyme replacement therapy
    Karageorgeos, L
    Harmatz, P
    Simon, J
    Pollard, A
    Clements, PR
    Brooks, DA
    Hopwood, JJ
    HUMAN MUTATION, 2004, 23 (03) : 229 - 233
  • [2] Mutational analysis of mucopolysaccharidosis type VI patients undergoing a phase II trial of enzyme replacement therapy
    Karageorgos, Litsa
    Brooks, Doug A.
    Harmatz, Paul
    Ketteridge, David
    Pollard, Anthony
    Melville, Elizabeth L.
    Parkinson-Lawrence, Emma
    Clements, Peter R.
    Hopwood, John J.
    MOLECULAR GENETICS AND METABOLISM, 2007, 90 (02) : 164 - 170
  • [3] Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy
    Donida, Bruna
    Marchetti, Desiree P.
    Biancini, Giovana B.
    Deon, Marion
    Manini, Paula R.
    da Rosa, Helen T.
    Moura, Dinara J.
    Saffi, Jenifer
    Bender, Fernanda
    Burin, Maira G.
    Coitinho, Adriana S.
    Giugliani, Roberto
    Vargas, Carmen Regla
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2015, 1852 (05): : 1012 - 1019
  • [4] Oxidative stress in patients with mucopolysaccharidosis type II before and during enzyme replacement therapy
    Filippon, Leticia
    Vanzin, Camila S.
    Biancini, Giovana B.
    Pereira, Izabela N.
    Manfredini, Vanusa
    Sitta, Angela
    Peralba, Maria do Carmo R.
    Schwartz, Ida V. D.
    Giugliani, Roberto
    Vargas, Carmen R.
    MOLECULAR GENETICS AND METABOLISM, 2011, 103 (02) : 121 - 127
  • [5] Enzyme replacement therapy in mucopolysaccharidosis type I
    Miebach, E
    ACTA PAEDIATRICA, 2005, 94 : 58 - 60
  • [6] Enzyme replacement therapy for mucopolysaccharidosis type I in Japan
    Okuyama, T.
    Tanaka, T.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2008, 31 : 119 - 119
  • [7] CARDIAC EVALUATION IN MUCOPOLYSACCHARIDOSIS PATIENTS UNDERGOING ENZYME REPLACEMENT THERAPY
    Brands, M. M. M. G.
    Hagemans, M. L. C.
    Hop, W. C.
    Helbing, W. A.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2010, 33 : S157 - S157
  • [8] Enzyme replacement therapy in mucopolysaccharidosis type I: The sooner the better
    Coppa, Giovanni V.
    Baldoni, Irene
    Bruni, Stefano
    Gabrielli, Orazio
    CLINICAL THERAPEUTICS, 2007, 29 : S83 - S83
  • [9] Laronidase (Aldurazyme®):: enzyme replacement therapy for mucopolysaccharidosis type I
    Pastores, Gregory M.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (07) : 1003 - 1009
  • [10] Risk for carpal tunnel syndrome in patients with mucopolysaccharidosis type I on enzyme replacement therapy
    Teunissen, Q. G. A.
    Hollak, C. E. M.
    Wijburg, F. A.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2008, 31 : 117 - 117